Drug Trial Radar · NCT07436689
Long-Term Open-Label Extension Study of Oral Levosimendan
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
800
Planned (sponsor's estimate)
Start
Mar 13, 2026
Primary completion
Mar 2029
Study completion Mar 2029
Sponsor
- Lead sponsor
- Tenax Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to provide continued access to treatment with oral levosimendan (TNX-103) and to describe the safety of continued use of TNX-103 in participants with pulmonary hypertension with heart failure with preserved left ventricular ejection fraction (PH-HFpEF) who received TNX-103 in a parent study.
Conditions
- Pulmonary Hypertension Associated With HFpEF
Interventions
TNX-103Drug
Open-label oral levosimendan 1-3mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence (i.e., the percentage of patients who experience at least 1 occurrence) of select AE/SAEsTime frame: From enrollment through study completion (up to 3 years)
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Tenax Investigational Site
Chicago, Illinois
Tenax Investigational Site
Boston, Massachusetts
Tenax Investigational Site
Minneapolis, Minnesota
Tenax Investigational Site
Rochester, Minnesota
Tenax Investigational Site
St Louis, Missouri
Tenax Investigational Site
Omaha, Nebraska
Tenax Investigational Site
New York, New York
Tenax Investigational Site
Durham, North Carolina
Tenax Investigational Site
Charleston, South Carolina
Tenax Investigational Site
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.